Mertin J
Fortschr Med. 1980 Oct 2;98(37):1431-6.
The results of various uncontrolled trials of immunosuppression in the treatment of multiple sclerosis have indicated an amelioration in the clinical course of the disease in about half of the treated patients. These observations have recently been confirmed by the findings in a double blind controlled study. The aim of future clinical trials has to lay in increasing the efficacy of conventional immunosuppressive agents in the treatment of multiple sclerosis. Further progress in immunological research and a better understanding of the etiology of multiple sclerosis may allow one day a more specific immunotherapy with the help of immunoregulatory substances.
各种关于免疫抑制治疗多发性硬化症的非对照试验结果表明,约一半接受治疗的患者病情临床进程有所改善。这些观察结果最近已被一项双盲对照研究的发现所证实。未来临床试验的目标必须是提高传统免疫抑制剂治疗多发性硬化症的疗效。免疫学研究的进一步进展以及对多发性硬化症病因的更好理解,可能有朝一日借助免疫调节物质实现更具针对性的免疫治疗。